Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clarity Medical Systems Inc.

This article was originally published in Start Up

Executive Summary

For all intents and purposes, ophthalmologists and optometrists are using the same screening and imaging technologies for diagnosing eye disorders that they have used for the past century. Clarity Medical Systems intends to disrupt the status quo with a single platform that physicians can use to screen, evaluate and one day potentially treat eye disease.

You may also be interested in...



An Early Peek at Glaucoma Devices

The clinical community has long been searching for a safe and effective surgical alternative to drugs for glaucoma, but the field has moved slowly. A decade ago, non-invasive laser procedures began earning a place as a second-line therapy with limited durability. Invasive surgeries are reserved for end-stage glaucoma because of their complexity, their serious complications, and their high failure rates. Venture firms believe a large, unmet clinical need represents a new $1 billion device market, and the pace of glaucoma device company creation is picking up.

From The Foundry, an Incubator Focused on Ophthalmology

The Foundry has created a new incubator to focus on ophthalmology, Forsight Labs, in partnership with Eugene de Juan, MD, a leading ophthalmologist and serial entrepreneur, who was one of the founders of Second Sight, and InnoRx.

Presbyopia at Arm's Length

VCs have funded at least a dozen start-ups working in presbyopia, including C&C Vision, whose founder Stuart Cumming has been quietly working on an accomodating intraocular lens for more than ten years. With the FDA's Ophthalmic Devices Panel unanimously recommending premarket approval of C&C Vision's CrystaLens accommodating intraocular lens for cataract patients, his firm is very close to being able to reap a first-mover advantage in this new market.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel